CSI Market
Sign In | Register

Kronos Bio Inc (KRON) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access KRON Annual Cash Flow →
A period-by-period view of cash flow from Kronos Bio Inc to Mar 31 2024 helps clarify how Mar 31 2025's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2025)
3 Months 		(Dec 31 2024) (Sep 30 2024) (Jun 30 2024) (Mar 31 2024)
Operating Activities
Income-8.36
Depreciation & amortization0.22
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring Costs and Asset Impairment Charges3.07
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Lease Expense Noncash-
Fair Value Option Changes In Fair Value Gain Loss-
Increase Decrease In Right Of Use Operating Assets And Liabilities Net-
Increase Decrease In Right Of Use Operating Assets And Lease Liabilities Net-
Share Based Payment Arrangement Noncash Expense Excluding Restructuring0.14
Increase Decrease In Operating Lease Liability-0.81
Operating Lease Right Of Use Asset Amortization Expense0.13
Income taxes0.00
Unrealized Gain (Loss) on Investments0.04
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-0.83
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-4.85
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.45
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2.03
Discontinued operations0.00
Net Cash flow from Operating Activities-12.84
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities24.30
Payments to Acquire Available-for-sale Securities, Debt-4.45
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities19.85
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-87.44
Finance Lease Principal Payments-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents86.60
Capital Expenditures Incurred But Not Yet Paid0.84
Right Of Use Asset Increase Decrease Due To Modification-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-12.84
Total Cash Flow7.01
4 historic quarters locked

Sign in to unlock the full Kronos Bio Inc cash flow history.

Sign In Create Free Account

About Kronos Bio Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001741830-25-000024

Figures are derived from filed reports and may be restated. Historical data is subject to revision.